难治性泌乳素瘤药物治疗进展

摘要: 泌乳素瘤是最常见的功能性垂体腺瘤，大部分泌乳素瘤患者通过多巴胺受体激动药物手术及放疗等常规治疗可以得到满意的疗效，但有部分泌乳素瘤患者呈耐药性，对多巴胺受体激动药抵抗，呈侵袭性生长，难以手术全切，术后复发率高，放疗效果不佳。这种难治性泌乳素瘤对神经外科医师提出巨大的治疗挑战，探索有效的治疗方法是目前亟待解决的难题。本文对难治性泌乳素瘤除目前常规治疗以外的新颖的探索性药物治疗进展进行综述，以期为临床提供新的治疗思维。
- 泌乳素瘤 /
- 耐药性 /
- 侵袭性 /
- 难治性
Abstract: Prolactinomas are the most common functional pituitary adenomas. Most patients with prolactinomas can achieve satisfactory results through conventional treatment such as dopamine agonist administration, surgery, and radiotherapy, but some prolactinomas are characterized by drug resistance. These tumors show resistance to treatment with dopamine agonists and frequently, invasive growth, making total surgical resection of the tumor difficult; these characteristics are coupled with a high postoperative recurrence rate and poor response to radiotherapy. Such refractory prolactinomas pose a great challenge to neurosurgeons. Refractory prolactinomas represent an urgent problem necessitating further exploration for effective treatment options. In this paper, we briefly review the advances in novel exploratory drug treatment for refractory prolactinomas in addition to conventional treatment, to highlight some new therapeutic approaches that can be used in clinical practice.
- prolactinoma /
- resistance /
- invasiveness /
- refractory

HTML全文

参考文献(48)

[1]	Olarescu NC, Perez-Rivas LG, Gatto F, et al. Aggressive and malignant prolactinomas[J]. Neuroendocrinology, 2019, 109(1):57-69.
[2]	Liu YT, Liu F, Cao L, et al. The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment[J]. Acta Neuropathol, 2020, 140(3):377-396. doi: 10.1007/s00401-020-02180-4
[3]	Raverot G, Burman P, McCormack A, et al. European society of endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas[J]. Eur J Endocrinol, 2018, 178(1):G1-G24.
[4]	Bruno OD, Juárez-Allen L, Christiansen SB, et al. Temozolomide therapy for aggressive pituitary tumors:results in a small series of patients from argentina[J]. Int J Endocrinol, 2015, 2015:587893. http://pubmedcentralcanada.ca/pmcc/articles/pmid/26106414
[5]	Almalki MH, Aljoaib NN, Alotaibi MJ, et al. Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas:a systematic review[J]. Hormones (Athens), 2017, 16(2):139-149. http://europepmc.org/abstract/MED/28742502
[6]	Kaltsas GA, Mukherjee JJ, Plowman PN, et al. The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors[J]. J Clin Endocrinol Metab, 1998, 83(12):4233-4238. http://jnnp.bmj.com/external-ref?access_num=10.1210/jc.83.12.4233&link_type=DOI
[7]	Souteiro P, Karavitaki N. Dopamine agonist resistant prolactinomas:any alternative medical treatment[J]? Pituitary, 2020, 23(1):27-37. doi: 10.1007/s11102-019-00987-3
[8]	Sosa-Eroza E, Espinosa E, Ramírez-Rentería C, et al. Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR[J]. Endocrine, 2018, 61(2):343-348. http://europepmc.org/abstract/MED/29948930
[9]	Lasolle H, Vasiljevic A, Borson-Chazot F, et al. Pasireotide:A potential therapeutic alternative for resistant prolactinoma[J]. Ann Endocrinol (Paris), 2019, 80(2):84-88. http://www.sciencedirect.com/science/article/pii/S0003426618312551
[10]	Choudhary C, Hamrahian AH, Bena JF, et al. The effect of raloxifene on serum prolactin level in patients with prolactinoma[J]. Endocr Pract, 2019, 25(7):684-688. http://www.ncbi.nlm.nih.gov/pubmed/30865525
[11]	Völker W, Gehring WG, Berning R, et al. Impaired pituitary response to bromocriptine suppression:reversal after bromocriptine plus tamoxifen[J]. Acta Endocrinol, 1982, 101(4):491-500. doi: 10.1530/acta.0.1010491
[12]	Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas[J]. Endocr Rev, 2006, 27(5):485-534. http://academic.oup.com/edrv/article/27/5/485/2355195
[13]	卢训西, 国琳玮, 李小光, 等.PI3K/AKT/mTOR通路及其抑制剂在乳腺癌中的应用现状[J].中国癌症杂志, 2020, 30(2):154-160. http://www.cnki.com.cn/Article/CJFDTotal-ZGAZ202002013.htm
[14]	Zhang D, Way JS, Zhang X, et al. Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas[J]. J Clin Endocrinol Metab, 2019, 104(6):1929-1936. http://www.ncbi.nlm.nih.gov/pubmed/30624667
[15]	Xie R, He WQ, Shen M, et al. Specific inhibition of mTOR pathway induces anti-proliferative effect and decreases the hormone secretion in cultured pituitary adenoma cells[J]. J Neurooncol, 2015, 125(1):79-89. http://www.ncbi.nlm.nih.gov/pubmed/26297046
[16]	董文靓, 王家雪, 张坦, 等.表皮生长因子受体靶向药物的研究现状[J].中国临床药理学杂志, 2020, 36(10):1377-1380. http://med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_zglcylxzz202010057
[17]	Cooper O, Mamelak A, Bannykh S, et al. Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors[J]. Endocrine, 2014, 46(2):318-327. http://pubmedcentralcanada.ca/pmcc/articles/PMC4037394/
[18]	Liu X, Kano M, Araki T, et al. ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice[J]. Endocrinology, 2015, 156(1):71-79. http://europepmc.org/articles/pmc4272404
[19]	中华医学会妇科肿瘤学分会.妇科肿瘤抗血管内皮生长因子单克隆抗体临床应用指南[J].中国医学前沿杂志(电子版), 2020, 12(1):27-34. http://d.wanfangdata.com.cn/periodical/xdfckjz202002001
[20]	Takano S, Akutsu H, Hara T, et al. Correlations of vascular architecture and angiogenesis with pituitary adenoma histotype[J]. Int J Endocrinol, 2014, 2014:989574. http://www.ncbi.nlm.nih.gov/pubmed/25431591
[21]	Li N, Jiang Z. Relationship between expression of vascular endothelial growth factor and the proliferation of prolactinomas[J]. Clin Neurol Neurosurg, 2017, 153:102-106. http://smartsearch.nstl.gov.cn/paper_detail.html?id=22709cd1b49083053b8ae25439f95153
[22]	Wang Y, Li J, Tohti M, et al. The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas:a study of 197 cases and indications for the medical therapy[J]. J Exp Clin Cancer Res, 2014, 33(1):56. http://intl-neuro-oncology.oxfordjournals.org/external-ref?access_num=10.1186/s13046-014-0056-y&link_type=DOI
[23]	Chauvet N, Romanò N, Lafont C, et al. Complementary actions of dopamine D2 receptor agonist and anti-vegf therapy on tumoral vessel normalization in a transgenic mouse model[J]. Int J Cancer, 2017, 140(9):2150-2161. doi: 10.1002/ijc.30628/abstract
[24]	甘丹娜, 王灿茂, 宋少练, 等.神经生长因子对周围神经损伤治疗作用的研究进展[J].中南药学, 2019, 17(12):2100-2103. http://d.wanfangdata.com.cn/periodical/znyx201912018
[25]	Fiorentini C, Guerra N, Facchetti M, et al. Nerve growth factor regulates dopamine D(2) receptor expression in prolactinoma cell lines via p75(NGFR)-mediated activation of nuclear factor-kappaB[J]. Mol Endocrinol, 2002, 16(2):353-366. http://europepmc.org/abstract/MED/11818506
[26]	Missale C, Losa M, Boroni F, et al. Nerve growth factor and bromocriptine:a sequential therapy for human bromocriptine-resistant prolactinomas[J]. Br J Cancer, 1995, 72(6):1397-1399. http://www.nature.com/articles/bjc1995520
[27]	Recouvreux MV, Faraoni EY, Camilletti MA, et al. Sex differences in the pituitary TGFβ1 system:The role of TGFβ1 in prolactinoma development[J]. Front Neuroendocrinol, 2018, 50:118-122.
[28]	Li Z, Liu Q, Li C, et al. The role of TGF-β1/Smad signaling in dopamine agonist-resistant prolactinomas[J]. Mol Cell Endocrinol, 2015, 402:64-71. http://europepmc.org/abstract/med/25578603
[29]	Recouvreux MV, Camilletti MA, Rifkin DB, et al. Thrombospondin-1(TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1(TGF-β1)[J]. Endocrinology, 2012, 153(8):3861-3871. http://www.ncbi.nlm.nih.gov/pubmed/22700773
[30]	Elenkova A, Atanassova I, Kirilov G, et al. Transforming growth factorβ 1 is not a reliable biomarker for valvular fibrosis but could be a potential serum marker for invasiveness of prolactinomas (pilot study)[J]. Eur J Endocrinol, 2013, 169(3):299-306. http://www.ncbi.nlm.nih.gov/pubmed/23801826
[31]	Hu B, Mao Z, Jiang X, et al. Role of TGF-β1/Smad3-mediated fibrosis in drug resistance mechanism of prolactinoma[J].Brain Res, 2018, 1698:204-212. http://www.sciencedirect.com/science/article/pii/S0006899318304086
[32]	Li C, Xie W, Rosenblum JS, et al. Somatic SF3B1 hotspot mutation in prolactinomas[J]. Nat Commun, 2020, 11(1):2506. http://www.nature.com/articles/s41467-020-16052-8
[33]	苗亚洲, 谢微嫣, 李储忠, 等.Pou6f2基因对泌乳素腺瘤MMQ细胞增殖和分泌能力的影响[J].山东医药, 2019, 59(14):19-22. http://www.cnki.com.cn/Article/CJFDTotal-SDYY201914005.htm
[34]	Zhong S, Wu B, Wang X, et al. Identification of driver genes and key pathways of prolactinoma predicts the therapeutic effect of genipin[J]. Mol Med Rep, 2019, 20(3):2712-2724. http://www.researchgate.net/publication/334548446_Identification_of_driver_genes_and_key_pathways_of_prolactinoma_predicts_the_therapeutic_effect_of_genipin
[35]	Dong W, Li J, Liu Q, et al. P21Waf1/Cip1 and p27Kip1 are correlated with the development and invasion of prolactinoma[J]. J Neurooncol, 2018, 136(3):485-494. doi: 10.1007/s11060-017-2683-6
[36]	王环宇, 吕洋, 许雪峰.肽受体放射性核素治疗在胃肠胰神经内分泌肿瘤中的应用进展[J].中华消化外科杂志, 2018, 17(7):763-766. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xhwk201807022
[37]	Giuffrida G, Ferrau F, Laudicella R, et al. Peptide receptor radionuclide therapy for aggressive pituitary tumors:a monocentric experience[J]. Endocr Connect, 2019, 8(5):528-535. http://www.ncbi.nlm.nih.gov/pubmed/30939449
[38]	Maclean J, Aldridge M, Bomanji J, et al. Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma:variable clinical response in preliminary evaluation[J]. Pituitary, 2014, 17(6):530-538. http://europepmc.org/abstract/med/24323313
[39]	王志, 黄秋林.肽受体放射性核素治疗胃肠胰神经内分泌肿瘤[J].现代肿瘤医学, 2017, 25(16):2685-2688. http://d.wanfangdata.com.cn/Periodical/sxzlyx201716041
[40]	张密, 董倩.三阴性乳腺癌免疫治疗的研究进展[J].中国肿瘤, 2020, 29(8):614-620.
[41]	Wang PF, Wang TJ, Yang YK, et al. The expression profile of PD-L1 and CD8⁺ lymphocyte in pituitary adenomas indicating for immunotherapy[J]. J Neurooncol, 2018, 139(1):89-95. doi: 10.1007/s11060-018-2844-2
[42]	Hazrati SM, Aghazadeh J, Mohtarami F, et al. Immunotherapy of prolactinoma with a T helper 1 activator adjuvant and autoantigens:a case report[J]. Neuroimmunomodulation, 2006, 13(4):205-208. http://europepmc.org/abstract/MED/17337912
[43]	Mei Y, Bi WL, Greenwald NF, et al. Increased expression of programmed death ligand 1(PD-L1) in human pituitary tumors[J]. Oncotarget, 2016, 7(47):76565-76576. http://pubmedcentralcanada.ca/pmcc/articles/PMC5363530/
[44]	靳凯, 阮伦亮, 蒲九君, 等.二甲双胍对大鼠催乳素瘤MMQ细胞增殖和凋亡的影响及机制[J].细胞与分子免疫学志, 2017, 33(5):643-648.
[45]	Liu X, Liu Y, Gao J, et al. Combination treatment with bromocriptine and metformin in patients with bromocriptine-resistant prolactinomas:pilot study[J]. World Neurosurg, 2018, 115:94-98. http://www.ncbi.nlm.nih.gov/pubmed/29530699
[46]	Lefort S, Joffre C, Kieffer Y, et al. Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triplenegative breast cancers[J]. Autophagy, 2014, 10(12):2122-2142. doi: 10.4161/15548627.2014.981788
[47]	Rosenfeld MR, Ye X, Supko JG, et al. A phase Ⅰ/Ⅱ trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme[J]. Autophagy, 2014, 10(8):1359-1368. doi: 10.4161/auto.28984
[48]	Lin SJ, Wu ZR, Cao L, et al. Pituitary Tumor Suppression by Combination of Cabergoline and Chloroquine[J]. J Clin Endocrinol Metab, 2017, 102(10):3692-3703. http://www.ncbi.nlm.nih.gov/pubmed/28973192